PulmonxLUNG
Market Cap: $336M
About: Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Employees: 279
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
5% less funds holding
Funds holding: 117 [Q1] → 111 (-6) [Q2]
6.95% less ownership
Funds ownership: 96.45% [Q1] → 89.5% (-6.95%) [Q2]
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
36% less capital invested
Capital invested by funds: $345M [Q1] → $220M (-$124M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Piper Sandler Jason Bednar 56% 1-year accuracy 23 / 41 met price target | 40%upside $12 | Overweight Maintained | 1 Aug 2024 |
Canaccord Genuity Jon Young 83% 1-year accuracy 5 / 6 met price target | 87%upside $16 | Buy Maintained | 1 Aug 2024 |
Wells Fargo Larry Biegelsen 79% 1-year accuracy 30 / 38 met price target | 17%upside $10 | Equal-Weight Maintained | 1 Aug 2024 |
Financial journalist opinion
Based on 3 articles about LUNG published over the past 30 days